Bausch+Lomb Results Presentation Deck
Pipeline and Upcoming Milestones¹
Surgical
Product
enVista Envy TM
en Vista® Trifocal IOL (Intraocular Lens)
Stable Visc TM Cohesive OVD
en Vista Aspire ™
en Vista® Extended Range Monofocal IOL
en Vista Dynamic ™
en Vista® Extended Depth of Focus IOL
Lux Premium IOL
Next Generation Surgical Platform
System 202x
eyeTELLIGENCE® Digital Platform
3D Microscope
Teneo TM Excimer Laser
BAUSCH + LOMB
Status
Canada, EU and U.S submissions in progress
Clinical Study Report completed 2Q22;
FDA submission filed early 3Q22
US and Canada submitted 1Q23
EU submission planned for 2Q 23
Clinical study to begin 3Q23
Launched in Europe
Alpha-2 prototype testing in progress
Beta software testing ongoing. Regulatory
assessments complete.
Preparing Myopia FDA submission
US hyperopia study on track
1. See slide 1 for further information on forward-looking statements.
Upcoming Milestone
Expect US, EU, Canada launch in 2024
(includes Toric versions and new EyeGility inserter)
Expect US approval/launch 2Q23
Expect US and Canada launch 2H23
(includes Toric; new Eye Gility inserter to be added in 2024)
EU launch expected in 2024 with EyeGility
inserter
Expect 2025/2026 launch
Continued expansion of platform expected in
2023
Beta prototyping expected 2023
US commercial release expected 1Q23
Launch expected in 2Q23
Expected myopia launch in U.S. in 2023;
US hyperopia Phase 1 data expected in 1Q23
30View entire presentation